en · de · es · pt
thymosin-alpha-1-notes.peptides3626.com › Wiki › Background And Molecular Profile — Hands-On Walkthrough

Background And Molecular Profile — Hands-On Walkthrough

By Editorial Desk · published 2025-08-04 · last reviewed 2025-08-30 · Wiki

Everything below concerns Immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-08-30. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Molecular Profile

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

Molecular Background and Immune Action

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Chemical classAcetylated peptideN-terminal acetyl group blocks aminopeptidase attack
Residue count28 amino acidsMatches the N-terminus of prothymosin alpha
Molecular massAbout 3,108 DaValue for the free, unmodified peptide
Isoelectric pointApproximately 4.2Acidic; net negative charge at neutral pH
Encoding genePTMAHuman gene for the precursor protein

Background, Structure, and Mechanism

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Related pages on this site

Background and Molecular Identity

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.

Background and Mechanism of Action

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Research History and Clinical Assessment

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Supporting material

== Video games == Games created during this time period often used a motif of nuclear war, as was the threat at that time. Some of the games listed have been made after the conclusion of the Cold War, but feature a central plot point around the Cold War.

Ukraine's long-term prosperity and security Regional peace and stability in the Middle East Cooperation to increase security and resilience across the Indo-Pacific Building stability and resilience in Haiti and Venezuela Supporting lasting peace in Sudan and the Democratic Republic of the Congo Strengthening sanctions and countering hybrid warfare and sabotage

==== Research and traditional medicine ==== Preliminary research indicates that the phytochemicals, betulin and possibly other triterpenes, are active in Episalvan gel and wound healing properties of birch bark. Over centuries, birch bark was used in traditional medicine practices by North American indigenous people for treating superficial wounds by applying bark directly to the skin. Splints made with birch bark were used as casts for broken limbs in the 16th century.

=== Artificial retina === The artificial retina of Professor José Sahel and his team at the Quinze-Vingts National Ophthalmology Hospital Centre aims to allow people with degenerative retinal disease, numbering 1.5 million in 2008, to accomplish everyday activities. Placed under the existing retina, it directly stimulates the neurons, replacing defective cells. These implants should eventually allow patients to recognize faces, read large print and move independently in a restricted environment. The challenge for the Altran teams was to find solutions to produce artificial retina in series, in order to bring solutions to the widest number of patients.

In the 12th and 13th centuries, crusades and conquest had subjugated Islamic territories in southern Italy, central Spain, and the Levant under European rule, and for the first time translations into Latin of the great works of Arabic and Greek scholars were made with the help of Jewish and Muslim scholars, especially in Toledo, which had fallen into Christian hands in 1085 and whose libraries had escaped destruction. Michael Scotus from Scotland made a Latin translation of Aristotle's work on animals from Arabic here around 1215, which was disseminated widely and was the first time in a millennium that this foundational text on zoology became available to Europeans. Falconry was popular in the Norman court in Sicily, and a number of works on the subject were written in Palermo. Emperor Frederick II of Hohenstaufen (1194–1250) learned about an falconry during his youth in Sicily and later built up a menagerie and sponsored translations of Arabic texts, among which the popular Arabic work known as the Liber Moaminus by an unknown author which was translated into Latin by Theodore of Antioch from Syria in 1240–1241 as the De Scientia Venandi per Aves, and also Michael Scotus (who had removed to Palermo) translated Ibn Sīnā's Kitāb al-Ḥayawān of 1027 for the Emperor, a commentary and scientific update of Aristotle's work which was part of Ibn Sīnā's massive Kitāb al-Šifāʾ.

Sources: en.wikipedia.org

Notes from published material

== Relevance to human disease == Possible implications of the SARM1 pathway with regard to human health may be found in animal models of neurodegeneration, where loss of SARM1 is neuroprotective in models of traumatic brain injury, chemotherapy-induced neuropathy, diabetic neuropathy, degenerative eye conditions, drug-induced Schwann cell death, Charcot-Marie-Tooth disease, and hereditary spastic paraplegia. Loss-of-function alleles of the SARM1 gene also occur naturally in the human population, potentially altering susceptibility to various neurological conditions. Specific mutations in the human NMNAT2 gene, encoding a key regulator of SARM1 activity, have linked the Wallerian degeneration mechanism to two human neurological diseases - fetal akinesia deformation sequence and childhood-onset polyneuropathy with erythromelalgia. Mutations in the human SARM1 gene that result in SARM1 protein with constitutive NADase activity have been reported in patients with amyotrophic lateral sclerosis (ALS).

transcription start site (TSS) Also transcription initiation site. The specific location within a gene at which RNA polymerase begins transcription, defined by the specific nucleotide or codon corresponding to the first ribonucleotide(s) to be assembled in the nascent transcript (which is not necessarily the same as the first codon to be translated). This site is usually considered the beginning of the coding sequence and is the reference point for numbering the individual nucleotides within a gene. Nucleotides upstream of the start site are assigned negative numbers and those downstream are assigned positive numbers, which are used to indicate the positions of nearby sequences or structures relative to the TSS. For example, the binding site for RNA polymerase might be a short sequence immediately upstream of the TSS, from approximately -80 to -5, whereas an intron within the coding region might be defined as the sequence starting at nucleotide +207 and ending at nucleotide +793.

His method of testing won the Intel International Science and Engineering Fair Gordon E. Moore Award in the spring of 2012. The Boeing Company has patented the use of carbon nanotubes for structural health monitoring of composites used in aircraft structures. This technology is hoped to greatly reduce the risk of an in-flight failure caused by structural degradation of aircraft. Zyvex Technologies has also built a 54' maritime vessel, the Piranha Unmanned Surface Vessel, as a technology demonstrator for what is possible using CNT technology. CNTs help improve the structural performance of the vessel, resulting in a lightweight 8,000 lb boat that can carry a payload of 15,000 lb over a range of 2,500 miles. IMEC is using carbon nanotubes for pellicles in semiconductor lithography. In tissue engineering, carbon nanotubes have been used as scaffolding for bone growth. Carbon nanotubes can serve as additives to various structural materials. For instance, nanotubes form a tiny portion of the material(s) in some (primarily carbon fiber) baseball bats, golf clubs, car parts, or damascus steel. IBM expected carbon nanotube transistors to be used on Integrated Circuits by 2020.

Stephanie Kate Howard, Moves and Operations Manager, Buckingham Palace Re-servicing Programme, Royal Household. Adelaide Georgina Gray Izat, Paintings Conservator, Royal Collection, Royal Household. Daniel James Kevin Johnson, Archbishop of Canterbury's Coronation Planning Director, on the occasion of the Coronation of Their Majesties The King and The Queen. Kevin Malkin, Detective Constable, Metropolitan Police Service. For services to Royalty Protection. Louise Michelle Walker-Pickett, Purchasing and Cost Control Co- ordinator, Royal Household. Nicola Jane Pritchard, Property Project Manager, Windsor Castle. Warrant Officer Class 1 David Alexander Roper, Grenadier Guards, 25131200; Superintending Clerk, Household Division, on the occasion of the Coronation of Their Majesties The King and The Queen. Warrant Officer Class 2 Julian Philip Desmond Sandford, Royal Corps of Army Music, 25152991; Sergeant Major, Band of the Household Cavalry, on the occasion of the Coronation of Their Majesties The King and The Queen. Christopher Charles Savage, lately Messenger Sergeant Major, The King's Body Guard of the Yeomen of the Guard. Derrick Andrew Scott, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Thomas Nicholas McKinlay Service, lately Acting Chief Operating Officer, Household of The Prince and Princess of Wales. Elizabeth Fiona St Clair, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Kathryn Elizabeth Stone, Paper Conservator, Royal Collection, Royal Household.

Sources: en.wikipedia.org

Background from the literature

== Route alignment == The Mumbai–Nagpur Expressway will travel through 10 key districts directly and 14 districts indirectly via feeder roads, 24 talukas, and 392 villages. The 10 main districts are Nagpur, Wardha, Amravati, Washim, Buldhana, Jalna, Aurangabad, Nashik, Ahmednagar, and Thane. The other 14 districts include Chandrapur, Bhandara, Gondia, Gadchiroli, Yavatmal, Akola, Hingoli, Parbhani, Nanded, Beed, Dhule, Jalgaon, Palghar, and Raigad. Yavatmal City is going to connect with Four Lane road to the Samruddhi Expressway and Amravati too. Four Lane Road will be constructed between Yavatmal City and Badnera.

=== Pre-release revenue === The film's pre-release rights for Darbar were sold for ₹220 crore (US$23 million). Tamil Nadu theatrical rights of the film were sold for ₹60 crore (US$6.2 million), rights in Kerala were sold for ₹6 crore (US$620,000).

Anti-acetylcholine receptors (anti-AChR) antibodies have also been detected in patients with thymoma, but without clinical manifestations of myasthenia gravis. There have also been reports of non-paraneoplastic limbic encephalitis associated with raised serum VGKC suggesting that these antibodies may give rise to a spectrum of neurological disease presenting with symptoms arising peripherally, centrally, or both. Yet, in two cases, oligoclonal bands were absent in the CSF and serum, and CSF immunoglobulin profiles were unremarkable.

Sources: en.wikipedia.org

Frequently asked questions

How does thymosin alpha 1 differ from thymosin fraction 5?

Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.

Which gene encodes the precursor protein?

The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.

Is the peptide found naturally in the human body?

It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.

What is thymosin alpha 1 made of?

It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.

Network